Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chen-Yang Su

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Metabolism: Clinical and Experimental|May 9, 2026
Data leakage and overadjustment bias in proteomic prediction models of mortality among cardiovascular-kidney-metabolic syndrome stage 0-3Zhenqian Wang, Chen-Yang Su, Sirui Zhou
Bioinformatics (Oxford, England)|November 8, 2024
MR Corge: sensitivity analysis of Mendelian randomization based on the core gene hypothesis for polygenic exposuresWenmin Zhang, Chen-Yang Su, Satoshi Yoshiji, et al.
Diabetes, Obesity & Metabolism|June 25, 2026
Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL TrialMasashi Hasebe, Chen-Yang Su, Daisuke Yabe, et al.
Current Osteoporosis Reports|October 10, 2025
Leveraging Proteomics and Proteogenomics for Understanding Osteoporosis and Other Musculoskeletal DiseasesMasashi Hasebe, Chen-Yang Su, Douglas P Kiel, et al.
Medrxiv : the Preprint Server for Health Sciences|June 12, 2026
Identifying circulating protein targets for common factors underlying schizophrenia, depression, and bipolar disorderJiaqi Duan, Chen-Yang Su, Satoshi Yoshiji, et al.
Diabetes, Obesity & Metabolism|January 21, 2026
GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trialMasashi Hasebe, Chen-Yang Su, Hisashi Kamido, et al.
Diabetes, Obesity & Metabolism|April 13, 2026
Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled TrialsMasashi Hasebe, Hisashi Kamido, Chen-Yang Su, et al.
Diabetes, Obesity & Metabolism|September 10, 2025
Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trialsMasashi Hasebe, Chen-Yang Su, Yamato Keidai, et al.
Circulation. Genomic and Precision Medicine|February 9, 2026
Phenome-Wide Mendelian Randomization Identifying Circulating Proteins for Cardiovascular Traits in Populations of African AncestrySusannah Selber-Hnatiw, Katerina Trajanoska, Justin Pelletier, et al.
International Journal of Epidemiology|February 11, 2023
Increasing serum iron levels and their role in the risk of infectious diseases: a Mendelian randomization approachGuillaume Butler-Laporte, Yossi Farjoun, Yiheng Chen, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Metabolism: Clinical and Experimental|May 9, 2026
Data leakage and overadjustment bias in proteomic prediction models of mortality among cardiovascular-kidney-metabolic syndrome stage 0-3Zhenqian Wang, Chen-Yang Su, Sirui Zhou
Bioinformatics (Oxford, England)|November 8, 2024
MR Corge: sensitivity analysis of Mendelian randomization based on the core gene hypothesis for polygenic exposuresWenmin Zhang, Chen-Yang Su, Satoshi Yoshiji, et al.
Diabetes, Obesity & Metabolism|June 25, 2026
Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL TrialMasashi Hasebe, Chen-Yang Su, Daisuke Yabe, et al.
Current Osteoporosis Reports|October 10, 2025
Leveraging Proteomics and Proteogenomics for Understanding Osteoporosis and Other Musculoskeletal DiseasesMasashi Hasebe, Chen-Yang Su, Douglas P Kiel, et al.
Medrxiv : the Preprint Server for Health Sciences|June 12, 2026
Identifying circulating protein targets for common factors underlying schizophrenia, depression, and bipolar disorderJiaqi Duan, Chen-Yang Su, Satoshi Yoshiji, et al.
Diabetes, Obesity & Metabolism|January 21, 2026
GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trialMasashi Hasebe, Chen-Yang Su, Hisashi Kamido, et al.
Diabetes, Obesity & Metabolism|April 13, 2026
Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled TrialsMasashi Hasebe, Hisashi Kamido, Chen-Yang Su, et al.
Diabetes, Obesity & Metabolism|September 10, 2025
Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trialsMasashi Hasebe, Chen-Yang Su, Yamato Keidai, et al.
Circulation. Genomic and Precision Medicine|February 9, 2026
Phenome-Wide Mendelian Randomization Identifying Circulating Proteins for Cardiovascular Traits in Populations of African AncestrySusannah Selber-Hnatiw, Katerina Trajanoska, Justin Pelletier, et al.
International Journal of Epidemiology|February 11, 2023
Increasing serum iron levels and their role in the risk of infectious diseases: a Mendelian randomization approachGuillaume Butler-Laporte, Yossi Farjoun, Yiheng Chen, et al.
Pageof 5